Aberdeen Group plc Increases Position in Edwards Lifesciences Corporation $EW

Key Points

• Aberdeen Group plc increased its holdings in Edwards Lifesciences Corporation by 10.1%, owning 522,175 shares valued at approximately $40.8 million as of the latest SEC filing.
• Numerous analysts have given Edwards Lifesciences positive ratings, with price targets ranging from $81 to $100, indicating a strong market outlook for the company.
• The recent quarterly earnings report showed Edwards Lifesciences exceeding expectations, reporting $0.67 EPS and $1.53 billion in revenue, a significant year-over-year revenue increase of 11.9%.

Aberdeen Group plc grew its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 10.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 522,175 shares of the medical research company's stock after acquiring an additional 47,872 shares during the period. Aberdeen Group plc owned about 0.09% of Edwards Lifesciences worth $40,839,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter worth $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences during the first quarter worth $27,000. Global X Japan Co. Ltd. raised its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares in the last quarter. Finally, Rossby Financial LCC purchased a new stake in Edwards Lifesciences during the first quarter valued at $29,000. Institutional investors own 79.46% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on EW shares. Evercore ISI set a $88.00 price target on shares of Edwards Lifesciences and gave the company an "outperform" rating in a research note on Tuesday, October 7th. Mizuho upped their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Finally, BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a research note on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $87.06.

Edwards Lifesciences Trading Down 1.6%

EW opened at $74.02 on Monday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The stock's fifty day moving average is $78.09 and its two-hundred day moving average is $76.17. The company has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a PEG ratio of 3.55 and a beta of 1.05. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.